研究概要
我们描绘了 reRCC 的异质性,并强调了一种创新机制,即 CAFs 通过 Gal1 充当 CD8+T 细胞的抑制因子。靶向 Gal1 联合 anti-PD1 在治疗 RCC 中显示出有希望的疗效。
研究思路结论见上方概要
目的
复发性肾细胞癌(reRCC)预后不良,其潜在机制尚不清楚。全面了解reRCC的肿瘤微环境(TME)可能有助于设计有效的抗癌疗法,包括免疫疗法。单细胞转录组学在研究TME方面具有巨大前景,然而该技术尚未应用于reRCC。在此,我们旨在单细胞水平上探索原发性肾细胞癌(pRCC)与reRCC之间TME和基因表达模式的差异。
方法
我们对来自2例pRCC、2例reRCC和3例癌旁正常肾组织的32,073个细胞进行了单细胞RNA测序分析。收集41对pRCC和reRCC样本作为验证队列,以评估单细胞测序中观察到的差异。在47例接受免疫治疗的RCC患者中研究了相关细胞和标志物的预后意义。通过体外和体内实验验证了相关细胞和标志物的功能。
结果
与pRCC相比,reRCC的CD8 + T细胞减少,但癌症相关成纤维细胞(CAFs)浸润增加。CD8 + T细胞减少和CAFs浸润增加与免疫治疗反应较差显著相关。值得注意的是,CAFs显示LGALS1(Gal1)的显著表达。在体外,CAFs可通过Gal1诱导CD8 + T细胞凋亡。在体内,敲低CAFs中的Gal1可抑制肿瘤生长,增加CD8 + T细胞浸润,降低凋亡CD8 + T细胞的比例,并增强免疫治疗的疗效。
展开英文摘要原文
PURPOSE
Recurrent renal cell carcinoma(reRCC) is associated with poor prognosis and the underlying mechanism is not yet clear. A comprehensive understanding of tumor microenvironment (TME) of reRCC may aid in designing effective anticancer therapies, including immunotherapies. Single-cell transcriptomics holds great promise for investigating the TME, however, this technique has not been used in reRCC. Here, we aimed to explore the difference in the TME and gene expression pattern between primary RCC (pRCC) and reRCC at single-cell level.
EXPERIMENTAL DESIGN: We performed single-cell RNA sequencing analyses of 32,073 cells from 2 pRCC, 2 reRCC, and 3 adjacent normal kidney samples. 41 pairs of pRCC and reRCC samples were collected as a validation cohort to assess differences observed in single-cell sequencing. The prognostic significance of related cells and markers were studied in 47 RCC patients underwent immunotherapy. The function of related cells and markers were validated via in vitro and in vivo experiments.
RESULTS
reRCC had reduced CD8 + T cells but increased cancer-associated fibroblasts (CAFs) infiltration compared with pRCC. Reduced CD8 + T cells and increased CAFs infiltration were significantly associated with a worse response from immunotherapy. Remarkably, CAFs showed substantial expression of LGALS1 (Gal1). In vitro, CAFs could induce CD8 + T cells apoptosis via Gal1. In vivo, knockdown of Gal1 in CAFs suppressed tumor growth, increased CD8 + T cells infiltration, reduced the proportion of apoptotic CD8 + T cells and enhanced the efficacy of immunotherapy.
CONCLUSIONS
We delineated the heterogeneity of reRCC and highlighted an innovative mechanism that CAFs acted as a suppressor of CD8 + T cells via Gal1. Targeting Gal1 combined with anti-PD1 showed promising efficacy in treating RCC.
论文信息
- 作者
- Peng YL、Xiong LB、Zhou ZH、Ning K、Li Z、Wu ZS、Deng MH、Wei WS
- 第一作者单位
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.China
- 通讯作者单位
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China zhangzhl@sysucc.org.cn zhoufj@sysucc.org.cn yuchp@sysucc.org.cn.China
- 文献类型
- 非美国政府资助研究
- 期刊
- Journal for immunotherapy of cancer2022 Feb